Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Genetic Testing

KRIT1 Gene Cerebral Cavernous Malformations Type 1 Genetic Test

Genetic test to identify mutations in the KRIT1 gene associated with Cerebral Cavernous Malformations (CCMs). Helps understand hereditary risk and guide management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), Extracted DNA, or one drop of blood on an FTA card.
Results
Confirm with the laboratory before booking. The source indicates approximately 3 to 4 weeks.
Preparation
Confirm with the laboratory before booking. A clinical history and family history (pedigree chart) may be required.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the KRIT1 Gene Cerebral Cavernous Malformations Type 1 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a personal or family history of Cerebral Cavernous Malformations (CCMs).
  • ✓Patients experiencing symptoms potentially related to CCMs, such as seizures or headaches.
  • ✓Family members of individuals diagnosed with CCMs.
  • ✓Assessing genetic risk for developing CCMs.
  • ✓Informing family planning decisions for those with a family history of CCMs.
02

In plain language

What this test helps you understand

Identifies mutations in the KRIT1 gene associated with Cerebral Cavernous Malformations (CCMs). This information can aid in understanding the genetic basis of the condition, assessing risk for affected individuals and family members, and potentially guiding management strategies.
The KRIT1 Gene Cerebral Cavernous Malformations Type 1 NGS Genetic DNA Test is a diagnostic tool used to analyze the KRIT1 gene. Mutations in this gene are linked to Cerebral Cavernous Malformations (CCMs), which are clusters of abnormal blood vessels in the brain that can cause neurological problems. This test uses Next-Generation Sequencing (NGS) technology to detect specific changes in the KRIT1 gene. Understanding these genetic changes can help in assessing the risk of developing CCMs and planning appropriate medical care. This test is particularly relevant for individuals with a family history of CCMs or those experiencing related symptoms. Genetic counseling is recommended to discuss the test and interpret the results.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. A clinical history and family history (pedigree chart) may be required.
SampleBlood sample (EDTA tube), Extracted DNA, or one drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) is used to detect mutations in the KRIT1 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the KRIT1 gene. It does not detect mutations in other genes associated with CCMs. A negative result does not completely rule out a genetic predisposition to CCMs. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CCMs are clusters of abnormal, thin-walled blood vessels in the brain. They can sometimes bleed, leading to neurological symptoms like seizures, headaches, or stroke-like symptoms.
Mutations in the KRIT1 gene are a known cause of hereditary CCMs. Identifying such mutations can help understand the cause of the condition in an individual or family.
Individuals with a personal or family history of CCMs, or those experiencing symptoms potentially related to CCMs, may be candidates for this test. Discuss with your doctor.
A positive result indicates that a mutation in the KRIT1 gene associated with CCMs was found. This can help confirm a genetic predisposition.
A negative result means no mutations in the KRIT1 gene were detected. However, CCMs can be caused by mutations in other genes or occur sporadically. Discuss the implications with your doctor.
Yes, genetic counseling is highly recommended before and after testing to understand the test's implications, interpret results, and discuss family planning or screening options.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Beta CTx Beta Crosslaps Collagen Type 1 C-Telopeptide Test

The Beta CTx test measures bone resorption markers to help assess bone health and osteoporosis risk.

Learn more →

Bcell Rearrangement Detection Test

The Bcell Rearrangement Detection Test helps diagnose leukemia by identifying genetic changes in B cells. It's a key tool for hematologists and oncologists.

Learn more →

Dpd Gene Mutations 5Fu Toxicity Detection Test

This genetic test identifies mutations in the DPD gene, helping predict the risk of severe side effects from the chemotherapy drug 5-fluorouracil (5FU).

Learn more →

Ganciclovir Resistance Detection Test

This test checks for genetic changes in the cytomegalovirus (CMV) that may make it resistant to the antiviral medication Ganciclovir. It helps guide treatment decisions, especially for patients with weakened immune systems.

Learn more →
Chat on WhatsApp